Ceptaris Therapeutics is categorized under Medical Research in Malvern, PA and active since 2013.
Ceptaris Therapeutics was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 8121990 by the NAICS.
If you are seeking more information, feel free to contact Stephen Tullman, Chief Executive Officer at the company’s single location by writing to 101 Lindenwood Drive # 400, Malvern, Pennsylvania PA 19355 or by phoning (610) 975-9290. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Ceptaris Therapeutics |
| Contact Person: | Stephen Tullman, Chief Executive Officer |
| Address: | 101 Lindenwood Drive # 400, Malvern, Pennsylvania 19355 |
| Phone Number: | (610) 975-9290 |
| Website Address: | ceptaris.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 8121990 |
| Share This Business: |
Ceptaris Therapeutics was started in 2013 to provide professional Medical Research under the SIC code 8733 and NAICS code 8121990. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Stephen Tullman, Chief Executive Officer for inquiries that concern Ceptaris Therapeutics by calling the company number (610) 975-9290, as your correspondence is most welcome. Additionally, the physical location of the single location of Ceptaris Therapeutics can be found at the coordinates 40.04981,-75.52752 as well as the street address 101 Lindenwood Drive # 400 in Malvern, Pennsylvania 19355.
For its online presence, you may visit Ceptaris Therapeutics’s website at ceptaris.com and engage with its social media outlets through on Twitter and on Facebook.